When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

And as of early November, there's one more big green flag suggesting that investors ... directly compete with the likes of Eli Lilly and Novo Nordisk, the big pharmas that currently split the ...

Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, ...

Demand for green power in the United States will grow regardless of who is the country's next president, major players in the ...

Novo Nordisk A/S (NYSE:NVO) just hit a technical red flag — a Death Cross. Chart created using Benzinga Pro For those ...

Novo Nordisk's Wegovy Sales Beat Expectations The ... Blackstone Real Estate Co-Head of Americas Acquisitions Jacob Werner said. Six Flags says consumers flocked to its parks in October Six ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...